The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Ligand-targeted liposome design: challenges and fundamental considerations
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems
Albanese, A., Tang, P. S., & Chan, W. C. W. (2012) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071811-150124 · Cited by 3,633
He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607
A review of stimuli-responsive nanocarriers for drug and gene delivery
Ganta, S., Devalapally, H., Shahiwala, A., & Amiji, M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.017 · Cited by 2,155
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149
Targeted drug delivery to tumors: Myths, reality and possibility
Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,561
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Malam, Y., Loizidou, M., & Seifalian, A. M. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.004 · Cited by 1,318
Parodi, A., Quattrocchi, N., van de Ven, A. L., Chiappini, C., Evangelopoulos, M., Martinez, J. O., Brown, B. S., Khaled, S. Z., Yazdi, I. K., Enzo, M. V., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.212 · Cited by 1,168
Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Girard, O. M., Hanahan, D., Mattrey, R. F., & Ruoslahti, E. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.013 · Cited by 1,136
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles
Rodriguez, P. L., Harada, T., Christian, D. A., Pantano, D. A., Tsai, R. K., & Discher, D. E. (2013) · Science · doi:10.1126/science.1229568 · Cited by 985
Canton, I., & Battaglia, G. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15309b · Cited by 936
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819
Macromolecular therapeutics in cancer treatment: The EPR effect and beyond
Maeda, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.038 · Cited by 814
Yeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis.
Lee, R. J., & Low, P. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41848-5 · Cited by 692
Nano/Microscale Motors: Biomedical Opportunities and Challenges
Wang, J., & Gao, W. (2012) · ACS Nano · doi:10.1021/nn3028997 · Cited by 668
Liposome application: problems and prospects.
Barenholz, Y. (2001) · Current Opinion in Colloid & Interface Science · doi:10.1016/s1359-0294(00)00090-x · Cited by 659
Perry, J. L., Reuter, K. G., Kai, M. P., Herlihy, K. P., Jones, S. W., Luft, J. C., Napier, M., Bear, J. E., & DeSimone, J. M. (2012) · Nano Letters · doi:10.1021/nl302638g · Cited by 606
Andresen, T. L., Jensen, S. S., & Jørgensen, K. (2005) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.12.001 · Cited by 580
Stealth nanoparticles: High density but sheddable PEG is a key for tumor targeting
Li, S.-D., & Huang, L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.016 · Cited by 562
Schroeder, A., Kost, J., & Barenholz, Y. (2009) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2009.08.003 · Cited by 485
Silverman, J. A., & Deitcher, S. R. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2042-4 · Cited by 474
Delivery of bioactive molecules into the cell: the Trojan horse approach
Dietz, G. P. H., & Bähr, M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.03.005 · Cited by 469
Gabizon, A., Horowitz, A. T., Goren, D., Tzemach, D., Mandelbaum-Shavit, F., Qazen, M. M., & Zalipsky, S. (1999) · Bioconjugate Chemistry · doi:10.1021/bc9801124 · Cited by 468
Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W.-L., Carter, P., Benz, C. C., & Papahadjopoulos, D. (1997) · Biochemistry · doi:10.1021/bi962148u · Cited by 439
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 438
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427
Peptides as Targeting Elements and Tissue Penetration Devices for Nanoparticles
Ruoslahti, E. (2012) · Advanced Materials · doi:10.1002/adma.201200454 · Cited by 419
Challenges in Development of Targeted Liposomal Therapeutics
Sawant, R. R., & Torchilin, V. P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9330-0 · Cited by 379
Liposomal paclitaxel formulations
Koudelka, Š., & Turánek, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.006 · Cited by 366
Dos Santos, N., Allen, C., Doppen, A.-M., Anantha, M., Cox, K. A. K., Gallagher, R. C., Karlsson, G., Edwards, K., Kenner, G., Samuels, L., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.12.013 · Cited by 341
Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin
Schiffelers, R. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00240-2 · Cited by 310
Ultrasound triggered release of cisplatin from liposomes in murine tumors
Schroeder, A., Honen, R., Turjeman, K., Gabizon, A., Kost, J., & Barenholz, Y. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.007 · Cited by 305
Hydration of Polyethylene Glycol-Grafted Liposomes
Tirosh, O., Barenholz, Y., Katzhendler, J., & Priev, A. (1998) · Biophysical Journal · doi:10.1016/s0006-3495(98)77849-x · Cited by 300
(2000) · PubMed · Cited by 295
In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizón, A., Horowitz, A. T., Goren, D., Tzemach, D., Shmeeda, H., & Zalipsky, S. (2003) · PubMed · Cited by 295
Forssen, E., & Willis, M. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00083-5 · Cited by 287
Hyperthermia mediated liposomal drug delivery
Ponce, A. M., Vujaskovic, Z., Yuan, F., Needham, D., & Dewhirst, M. W. (2006) · International Journal of Hyperthermia · doi:10.1080/02656730600582956 · Cited by 279
Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells
Laakkonen, P., Åkerman, M. E., Biliran, H., Yang, M., Ferrer, F., Karpanen, T., Hoffman, R. M., & Ruoslahti, E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403317101 · Cited by 275
Targeted delivery of doxorubicin using stealth liposomes modified with transferrin
Li, X., Ding, L., Xu, Y., Wang, Y., & Ping, Q. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.01.023 · Cited by 274
Maldiney, T., Richard, C., Seguin, J., Wattier, N., Bessodes, M., & Scherman, D. (2011) · ACS Nano · doi:10.1021/nn101937h · Cited by 272
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
de Menezes, D. E. L., Pilarski, L. M., & Allen, T. M. (1998) · PubMed · Cited by 257
Phototriggering of liposomal drug delivery systems
Shum, P., Kim, J.-M., & Thompson, D. H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00232-0 · Cited by 255
Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome
Suzuki, R., Takizawa, T., Kuwata, Y., Mutoh, M., Ishiguro, N., Utoguchi, N., Shinohara, A., Eriguchi, M., Yanagie, H., & Maruyama, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.010 · Cited by 250
Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.
Xu, L., Huang, C., Huang, W., Tang, W., Rait, A. S., Yin, Y. Z., Cruz, I., Xiang, L., Pirollo, K. F., & Chang, E. H. (2002) · PubMed · Cited by 243
Saad, M., Garbuzenko, O. B., Ber, E., Chandna, P., Khandare, J. J., Pozharov, V. P., & Minko, T. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.024 · Cited by 238
Steric Stabilization of Fusogenic Liposomes by a Low-pH Sensitive PEG−Diortho Ester−Lipid Conjugate
Guo, X., & Szoka, F. C. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000110v · Cited by 232
Transtumoral targeting enabled by a novel neuropilin-binding peptide
Roth, L., Agemy, L., Kotamraju, V. R., Braun, G., Teesalu, T., Sugahara, K. N., Hamzah, J., & Ruoslahti, E. (2012) · Oncogene · doi:10.1038/onc.2011.537 · Cited by 231
Hyperthermia-induced drug targeting
May, J. P., & Li, S.-D. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.758631 · Cited by 228
Hong, R. L., Huang, C. J., Tseng, Y., Pang, V. F., Chen, S.-T., Liu, J. J., & Chang, F. (1999) · PubMed · Cited by 227
Iinuma, H., Maruyama, K., Okinaga, K., Sasaki, K., Sekine, T., Ishida, O., Ogiwara, N., Johkura, K., & Yonemura, Y. (2002) · International Journal of Cancer · doi:10.1002/ijc.10242 · Cited by 216
Ishida, T., Kirchmeier, M. J., Moase, E. H., Zalipsky, S., & Allen, T. M. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00409-6 · Cited by 216
Wu, J. H., Lu, Y., Lee, A., Pan, X., Yang, X., Zhao, X. B., & Lee, R. J. (2007) · PubMed · Cited by 216
Li, L., ten Hagen, T. L. M., Hossann, M., Süss, R., van Rhoon, G. C., Eggermont, A. M. M., Haemmerich, D., & Koning, G. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.011 · Cited by 208
Kirpotin, D., Hong, K., Mullah, N., Papahadjopoulos, D., & Zalipsky, S. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00521-2 · Cited by 206
Stefanick, J. F., Ashley, J. D., Kiziltepe, T., & Bilgicer, B. (2013) · ACS Nano · doi:10.1021/nn305663e · Cited by 205
Self-citationEnzyme-triggered nanomedicine: Drug release strategies in cancer therapy (Invited Review)
Andresen, T. L., Thompson, D. H., & Kaasgaard, T. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.515950 · Cited by 200
Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
Solomon, R., & Gabizon, A. A. (2008) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2008.n.001 · Cited by 199
Targeting hepatocytes for drug and gene delivery emerging novel approaches and applications
Wu, J. (2002) · Frontiers in Bioscience · doi:10.2741/a806 · Cited by 190
Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery
Lo, A., Lin, C.-T., & Wu, H.-C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2359 · Cited by 179
Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies
Goren, D., Horowitz, A., Zalipsky, S., Woodle, M., Yarden, Y., & Gabizon, A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.625 · Cited by 179
Nielsen, U. B., Kirpotin, D. B., Pickering, E. M., Hong, K., Park, J. W., Refaat Shalaby, M., Shao, Y., Benz, C. C., & Marks, J. D. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00256-2 · Cited by 177
Nanoparticles disguised as red blood cells to evade the immune system
Fang, R. H., Hu, C.-M. J., & Zhang, L. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.661710 · Cited by 174
Kobayashi, T., Ishida, T., Okada, Y., Ise, S., Harashima, H., & Kiwada, H. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.08.039 · Cited by 170
Cheng, W. W. K., & Allen, T. M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.11.005 · Cited by 159
McNeeley, K. M., Karathanasis, E., Annapragada, A., & Bellamkonda, R. V. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.04.012 · Cited by 149
Zhang, Y., Wang, J., Bian, D., Zhang, X., & Zhang, Q. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.01.002 · Cited by 145
Xie, F., Xie, F., Qin, Yuan, Tang, Zhang, Fan, Chen, Hai, Yao, et al. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23771 · Cited by 142
Design of Folate-Linked Liposomal Doxorubicin to its Antitumor Effect in Mice
Yamada, A., Taniguchi, Y., Kawano, K., Honda, T., Hattori, Y., & Maitani, Y. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0159 · Cited by 141
Bandak, S., Goren, D., Horowitz, A. T., Tzemach, D., & Gabizon, A. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199911000-00007 · Cited by 137
Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity
Charrois, G. J. R., & Allen, T. M. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.053413 · Cited by 136
Hölig, P., Bach, M., Völkel, T., Nahde, T., Hoffmann, S., Müller, R., & Kontermann, R. E. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh055 · Cited by 129
Reynolds, J. G., Geretti, E., Hendriks, B. S., Lee, H., Leonard, S. C., Klinz, S. G., Noble, C. O., Lücker, P. B., Zandstra, P. W., Drummond, D. C., et al. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.04.008 · Cited by 122
Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells
Yang, T., Choi, M.-K., Fu-de, C., Lee, S. J., Chung, S., Shim, C., & Kim, D. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9425-y · Cited by 119
Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotoxicity
Laginha, K. M., Mumbengegwi, D. R., & Allen, T. M. (2005) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.02.007 · Cited by 119
McNeeley, K. M., Annapragada, A., & Bellamkonda, R. V. (2007) · Nanotechnology · doi:10.1088/0957-4484/18/38/385101 · Cited by 117
Gabizón, A., Tzemach, D., Gorin, J., Mak, L., Amitay, Y., Shmeeda, H., & Zalipsky, S. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1132-4 · Cited by 116
Maruyama, K. (2002) · Bioscience Reports · doi:10.1023/a:1020138622686 · Cited by 109
Takara, K., Hatakeyama, H., Kibria, G., Ohga, N., Hida, K., & Harashima, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.019 · Cited by 105
Hattori, Y., & Maitani, Y. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.03.007 · Cited by 102
Zhang, J., Wu, J., Wang, X., Wang, J., Zhang, X., & Zhang, Q. (2010) · Molecular Pharmaceutics · doi:10.1021/mp1000235 · Cited by 101
Chiu, S.-J., Liu, S., Perrotti, D., et al. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.02.011 · Cited by 96
Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma
Lee, R. J., Lee, R. J., Zhang, Yung, Li, Zhou, C., & Lee, L. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33965 · Cited by 94
Zhao, H., Wang, J., Sun, Q., Luo, C.-L., & Zhang, Q. (2008) · Journal of drug targeting · doi:10.1080/10611860802368966 · Cited by 92
Mendonça, L. S., Firmino, F., Moreira, J. N., de Lima, M. C. P., & Simões, S. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9004365 · Cited by 92
Koshkaryev, A., Piroyan, A., & Torchilin, V. P. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.1.18871 · Cited by 92
Kiziltepe, T., Ashley, J. D., Stefanick, J. F., Qi, Y. M., Alves, N. J., Handlogten, M. W., Suckow, M. A., Navari, R. M., & Bilgiçer, B. (2012) · Blood Cancer Journal · doi:10.1038/bcj.2012.10 · Cited by 91
Self-citationNanomedicine and the complement paradigm
Moghimi, S. M., & Farhangrazi, Z. S. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.02.011 · Cited by 89
Stefanick, J. F., Ashley, J. D., & Bilgiçer, B. (2013) · ACS Nano · doi:10.1021/nn4033954 · Cited by 88
Self-citationOvercoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro
Krieger, M. L., Eckstein, N., Schneider, V., Koch, M., Royer, H., Jaehde, U., & Bendas, G. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.12.061 · Cited by 84
A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin
Sankhala, K. K., Mita, A. C., Adinin, R., Wood, L. M., Beeram, M., Bullock, S., Yamagata, N., Matsuno, K., Fujisawa, T., & Phan, A. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2535 · Cited by 84
Vincristine: Can its therapeutic index be enhanced?
Moore, A. S., & Pinkerton, C. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22161 · Cited by 80
Effect of coupling of albumin onto surface of PEG liposome on its in vivo disposition
Furumoto, K., Yokoe, J.-I., Ogawara, K., AMANO, S., TAKAGUCHI, M., Higaki, K., Kai, T., & Kimura, T. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.08.026 · Cited by 79
Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo
Vingerhoeds, M. H., Steerenberg, P., Hendriks, J., Dekker, L., Hoesel, Q. V., Crommelin, D. J. A., & Storm, G. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.484 · Cited by 79
Kuai, R., Yuan, W., Li, W., Qin, Y., Tang, J., Yuan, M., Fu, L., Ran, R., Zhang, Z., & He, Q. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200100f · Cited by 76
Cancer-Specific Ligands Identified from Screening of Peptide-Display Libraries
Mori, T. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383944 · Cited by 76
Yu, B., Mao, Y., Bai, L., Herman, S. E. M., Wang, X., Ramanunni, A., Jin, Y., Mo, X. M., Cheney, C. M., Chan, K. K., et al. (2012) · Blood · doi:10.1182/blood-2012-01-407742 · Cited by 67
Morelli, G., Accardo, A., Tesauro, D., Cicala, C., Salzano, G., Rosa, G. D., Morisco, A., Aloj, L., Aurilio, M., Μaione, F., et al. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s29242 · Cited by 66
Design Principles for Clinical Efficacy of Cancer Nanomedicine: A Look into the Basics
Sengupta, S., & Kulkarni, A. A. (2013) · ACS Nano · doi:10.1021/nn4015399 · Cited by 65
Emanuel, N., Kedar, E., Bolotin, E. M., Smorodinsky, N. I., & Barenholz, Y. (1996) · Pharmaceutical Research · doi:10.1023/a:1016096910822 · Cited by 64
Chiu, G. N. C., Edwards, L., Kapanen, A. I., Malinen, M. M., Dragowska, W. H., Warburton, C., Chikh, G., Fang, K. Y. Y., Tan, S., Sy, J., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0159 · Cited by 59
Laginha, K. M., Moase, E. H., Yu, N. Y., Huang, A., & Allen, T. M. (2008) · Journal of drug targeting · doi:10.1080/10611860802229978 · Cited by 53
Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer
Piao, L., Li, H., Teng, L., Yung, B. C., Sugimoto, Y., Brueggemeier, R. W., & Lee, R. J. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.03.008 · Cited by 52
Galactose-Modified Cationic Liposomes as a Liver-Targeting Delivery System for Small Interfering RNA
Sonoke, S., Ueda, T., Fujiwara, K., Kuwabara, K., & Yano, J. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1338 · Cited by 46
Bandekar, A., Zhu, C., Gomez, A., Menzenski, M. Z., Sempkowski, M., & Sofou, S. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3002717 · Cited by 45
Wang, S., Xu, H., Xu, J., Zhang, Y., Liu, Y., Deng, Y., & Chen, D. (2010) · AAPS PharmSciTech · doi:10.1208/s12249-010-9450-8 · Cited by 42
Iwase, Y., & Maitani, Y. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100380y · Cited by 42
Zhang, X., Koh, C. G., Yu, B., et al. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9864-8 · Cited by 41
Targeting platelet function to improve drug delivery
Demers, M., & Wagner, D. D. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17962 · Cited by 32
Fang, C., Shi, B., & Pei, Y. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00537.x · Cited by 18
Cited by
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Liposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561
Design of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196
Attia, M. F., Anton, N., Wallyn, J., Omran, Z., & Vandamme, T. F. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13098 · Cited by 1,085
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2018.06.005 · Cited by 998
Metadata
- Authors
- Noble, G. T., Stefanick, J. F., Ashley, J. D., Kiziltepe, T., & Bilgicer, B.
- Venue
- Trends in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 32
- Issue
- 1
- Pages
- 32-45
- ISSN
- 0167-7799 (ISSN-L)
- OpenAlex
- W2048497409
- Cited by
- 542
- References
- 120
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.